{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:24:20Z","timestamp":1765545860634},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1097\/ftd.0b013e3182a94e65","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T08:52:08Z","timestamp":1384419128000},"page":"159-168","source":"Crossref","is-referenced-by-count":16,"title":["Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population"],"prefix":"10.1097","volume":"36","author":[{"given":"Virginia","family":"Bos\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Buso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Almenar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"S\u00e1nchez-L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"S\u00e1nchez-Plumed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Bea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Sole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador F.","family":"Ali\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":". Pharmacogenomics knowledge for personalized medicine.","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R2-6-20210129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trre.2007.09.002","article-title":"Pharmacogenetics in solid organ transplantation: current status and future directions.","volume":"22","author":"De Jonge","year":"2008","journal-title":"Transplant Rev (Orlando)"},{"key":"R3-6-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pharmthera.2004.11.001","article-title":"Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.","volume":"106","author":"Johnson","year":"2005","journal-title":"Pharmacol Ther"},{"key":"R5-6-20210129","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1016\/j.transproceed.2010.05.129","article-title":". Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation.","volume":"42","author":"Herrero","year":"2010","journal-title":"Transplant Proc"},{"key":"R6-6-20210129","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1016\/j.transproceed.2010.05.122","article-title":". Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation.","volume":"42","author":"Herrero","year":"2010","journal-title":"Transplant Proc"},{"key":"R7-6-20210129","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.transproceed.2011.05.008","article-title":". Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.","volume":"43","author":"Jordan de Luna","year":"2011","journal-title":"Transplant Proc"},{"key":"R8-6-20210129","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00228-007-0380-7","article-title":". Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.","volume":"63","author":"Miura","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R9-6-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":". Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"},{"key":"R10-6-20210129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":". The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R11-6-20210129","first-page":"721","article-title":". Optimization of initial tacrolimus dose using pharmacogenetic testing.","volume":"87","author":"Thervet","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R12-6-20210129","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3899\/jrheum.080576","article-title":"Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity.","volume":"36","author":"Fisher","year":"2009","journal-title":"J Rheumatol"},{"key":"R13-6-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"V, Gardner EE, Sandborn WJ, et al.. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R14-6-20210129","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.ftd.0000186914.32038.a0","article-title":". Differences in CYP3A53 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations.","volume":"27","author":"Gervasini","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R17-6-20210129","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/0091270005274507","article-title":". Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes.","volume":"45","author":"Zheng","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R18-6-20210129","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1097\/01.ASN.0000073901.94759.36","article-title":". Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.","volume":"14","author":"Anglicheau","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R19-6-20210129","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270003253617","article-title":". The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.","volume":"43","author":"Yates","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R20-6-20210129","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.TP.0000137789.58694.B4","article-title":". Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.","volume":"78","author":"Tsuchiya","year":"2004","journal-title":"Transplantation"},{"key":"R21-6-20210129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":". Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R22-6-20210129","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/FTD.0b013e31820feb8e","article-title":". Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.","volume":"33","author":"Bouamar","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R23-6-20210129","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.clinthera.2012.06.022","article-title":". ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis.","volume":"34","author":"Kim","year":"2012","journal-title":"Clin Ther"},{"key":"R24-6-20210129","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2133\/dmpk.DMPK-11-RG-066","article-title":". Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis.","volume":"27","author":"Kato","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R25-6-20210129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00007691-200302000-00016","article-title":". Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population.","volume":"25","author":"Bernal","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R26-6-20210129","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/FPC.0b013e32834a48ca","article-title":". Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.","volume":"21","author":"Tang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R27-6-20210129","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2217\/pgs.11.70","article-title":". Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.","volume":"12","author":"Santoro","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R28-6-20210129","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/TP.0b013e3181fa93a4","article-title":". CYP3A5 1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.","volume":"90","author":"Min","year":"2010","journal-title":"Transplantation"},{"key":"R29-6-20210129","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2407-7-118","article-title":". Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.","volume":"7","author":"Gervasini","year":"2007","journal-title":"BMC Cancer"},{"key":"R30-6-20210129","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.clpt.6100216","article-title":". CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.","volume":"82","author":"Kuypers","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R31-6-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/clpt.2008.95","article-title":". Pharmacogenetic pathway analysis of docetaxel elimination.","volume":"85","author":"Baker","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R32-6-20210129","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/ard.2005.046797","article-title":". Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.","volume":"65","author":"Hughes","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R33-6-20210129","first-page":"81","article-title":". Analysis of the frequencies of genotype combinations of 4 polymorphisms of genes acting on the folate cycle in the Spanish population in Spanish.","volume":"131","author":"Martinez-Frias","year":"2008","journal-title":"Med Clin (Barc)"},{"key":"R34-6-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-010-0154-4","article-title":". Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population.","volume":"100","author":"Kurzwelly","year":"2010","journal-title":"J Neurooncol"},{"key":"R35-6-20210129","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s004310051311","article-title":". Linkage disequilibrium of the common mutations 677C T and 1298A C of the human methylenetetrahydrofolate reductase gene as proven by the novel polymorphisms 129C T, 1068C T.","volume":"159","author":"Linnebank","year":"2000","journal-title":"Eur J Pediatr"},{"key":"R36-6-20210129","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bmt.1705330","article-title":". Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation.","volume":"37","author":"Robien","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R37-6-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/FPC.0b013e32834ded2a","article-title":". Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis.","volume":"22","author":"Spyridopoulou","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R38-6-20210129","doi-asserted-by":"crossref","first-page":"RRN1236","DOI":"10.1371\/currents.RRN1236","article-title":"Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk.","volume":"3","author":"Nguyen","year":"2011","journal-title":"PLoS Curr"},{"key":"R39-6-20210129","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","article-title":". Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.","volume":"14","author":"Schaeffeler","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R40-6-20210129","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bjp.0702152","article-title":". Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population.","volume":"125","author":"Spire-Vayron de la Moureyre","year":"1998","journal-title":"Br J Pharmacol"},{"key":"R41-6-20210129","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":". Pharmacogenetics: from bench to bytean update of guidelines.","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R43-6-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1124\/jpet.103.054072","article-title":". Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.","volume":"307","author":"Villeneuve","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R44-6-20210129","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1124\/dmd.107.015446","article-title":". Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.","volume":"35","author":"Ramirez","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R45-6-20210129","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/01.tp.0000235533.29300.e7","article-title":". Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.","volume":"82","author":"Naesens","year":"2006","journal-title":"Transplantation"},{"key":"R46-6-20210129","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cca.2011.12.003","article-title":". The association of the UGT1A8, SLCO1B3 and ABCC2ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.","volume":"413","author":"Geng","year":"2012","journal-title":"Clin Chim Acta"},{"key":"R47-6-20210129","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FTD.0b013e3181838063","article-title":". Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.","volume":"30","author":"Miura","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R48-6-20210129","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/pbc.23074","article-title":". Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.","volume":"57","author":"Lopez-Lopez","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R49-6-20210129","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2006.08.012","article-title":". High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.","volume":"80","author":"Rau","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R50-6-20210129","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":". Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"R51-6-20210129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/tpj.2011.7","article-title":". Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia.","volume":"12","author":"Chan","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"R52-6-20210129","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":". Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.","volume":"90","author":"Scott","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R53-6-20210129","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/jpet.106.104364","article-title":". Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.","volume":"318","author":"Badagnani","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R54-6-20210129","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2217\/pgs.10.132","article-title":". SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients.","volume":"11","author":"Michelon","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R55-6-20210129","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","article-title":". Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.","volume":"27","author":"Trevino","year":"2009","journal-title":"J Clin Oncol"},{"key":"R56-6-20210129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/clpt.2012.57","article-title":". The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.","volume":"92","author":"Wilke","year":"2012","journal-title":"Clin Pharmacol Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3182a94e65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:41:30Z","timestamp":1620952890000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201404000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3182a94e65","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}